Vancomycin-associated exfoliative dermatitis during continuous ambulatory peritoneal dialysis.

Area of Science:

• Nephrology
• Dermatology
• Infectious Diseases

Background:

• Vancomycin is a standard treatment for infections in patients on continuous ambulatory peritoneal dialysis (CAPD).
• Intraperitoneal vancomycin is generally considered safe in CAPD, with few reported dermatological side effects.
• Adverse skin reactions are more commonly associated with rapid intravenous vancomycin administration.

Observation:

• This case report details a CAPD patient with a history of systemic lupus erythematosus.
• The patient received intermittent intraperitoneal vancomycin for a catheter-related exit-site/tunnel infection.
• The patient developed erythema multiforme, which subsequently progressed to exfoliative dermatitis.

Findings:

• Intraperitoneal vancomycin therapy can precipitate severe dermatological reactions, such as erythema multiforme and exfoliative dermatitis.
• These reactions may occur even when vancomycin is administered via the intraperitoneal route in CAPD patients.
• The development of these reactions might be influenced by underlying conditions like systemic lupus erythematosus.

Implications:

• Clinicians should be vigilant for potential severe skin reactions in CAPD patients receiving intraperitoneal vancomycin, especially those with comorbidities.
• This case highlights the need for careful monitoring and consideration of alternative treatments if dermatological adverse events arise.
• Further investigation may be warranted to understand the specific mechanisms and risk factors for vancomycin-induced dermatological toxicity in the CAPD population.